Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes

J Immunol. 1991 Oct 1;147(7):2290-4.

Abstract

The CD2 T lymphocyte glycoprotein surface molecule mediates both cell to cell adhesion and T cell activation, two processes that are involved in the spread of HIV infection. Treatment of chronically HIV-infected PBMC with anti-CD2 mAb has been shown to induce the expression of infectious virus from these cultures. In this study we investigated the mechanisms whereby anti-CD2 antibodies stimulate viral production. We demonstrate that treatment of transiently transfected T lymphocytes with anti-CD2 antibodies results in activation of the HIV long terminal repeat. Furthermore, CAT assays using mutated HIV long terminal repeat-CAT constructs and gel shift assays demonstrate that this activation is dependent on the NF-kappa B enhancer. These studies suggest that interaction of CD2 with its natural ligand, LFA-3, may play a role in regulation of HIV expression.

MeSH terms

  • Antibodies, Monoclonal / immunology*
  • Antigens, Differentiation, T-Lymphocyte / immunology
  • Antigens, Differentiation, T-Lymphocyte / physiology*
  • CD2 Antigens
  • Enhancer Elements, Genetic
  • Gene Expression Regulation, Viral*
  • HIV Long Terminal Repeat*
  • Humans
  • NF-kappa B / physiology
  • Receptors, Immunologic / immunology
  • Receptors, Immunologic / physiology*
  • T-Lymphocytes / microbiology*
  • Transfection
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Antibodies, Monoclonal
  • Antigens, Differentiation, T-Lymphocyte
  • CD2 Antigens
  • NF-kappa B
  • Receptors, Immunologic
  • Tumor Necrosis Factor-alpha